Welcome to our dedicated page for Immatics N.V news (Ticker: IMTX), a resource for investors and traders seeking the latest updates and insights on Immatics N.V stock.
Immatics N.V. develops clinical-stage cancer immunotherapies built around T-cell receptor biology, with a stated focus on precision targeting of PRAME across solid tumors. News about IMTX most often covers clinical updates for PRAME-directed cell therapies and TCR bispecifics, including anzu-cel (anzutresgene autoleucel, IMA203), IMA203CD8, IMA402 and IMA401 MAGEA4/8. Company announcements also cover presentations at oncology meetings such as ASCO, AACR and ESMO, where Immatics reports safety, dose-escalation and anti-tumor activity data across melanoma, ovarian cancer, synovial sarcoma and other PRAME-positive cancers.
Recurring updates include financial results, business updates, collaboration activity, clinical and regulatory disclosures, leadership changes, shareholder voting matters and capital-structure disclosures for the Nasdaq-listed biotechnology company.
Immatics (NASDAQ: IMTX) announced positive interim results for its IMA203 TCR-T candidate, showing a 50% objective response rate in a Phase 1a trial targeting PRAME across multiple solid tumors. The company is set to initiate multiple Phase 1b expansion cohorts in Q2 2022, including monotherapy and combination therapies. Additionally, a global licensing agreement with Bristol Myers Squibb provides Immatics with a $150 million upfront payment and up to $770 million in potential milestone payments. As of December 31, 2021, cash reserves totaled $164 million, ensuring operational funding through 2024.
Bristol Myers Squibb (NYSE:BMY) reported Q4 revenues of $12.0 billion, an 8% increase driven by robust sales of Eliquis and immuno-oncology products. Full-year revenues reached $46.4 billion, up 9%. Q4 earnings per share (EPS) stood at $1.07 (GAAP) and $1.83 (non-GAAP), with annual EPS at $3.12 and $7.51 respectively. The company announced a $15 billion share repurchase authorization and provided 2022 guidance, predicting $47 billion in revenues. The outlook includes expected growth from new products and a reduction in operating expenses.
Bristol Myers Squibb (NYSE:BMY) has reported fourth quarter revenues of $12.0 billion, marking an 8% increase year-over-year, and full-year revenues of $46.4 billion. The fourth quarter earnings per share (EPS) stand at $1.07 (GAAP) and $1.83 (non-GAAP), with full-year EPS at $3.12 and $7.51 respectively, reflecting a 17% growth in non-GAAP EPS. The company has authorized a $15 billion share repurchase initiative and announced a $5 billion accelerated share repurchase agreement for Q1 2022. Guidance for 2022 includes projected revenues of approximately $47 billion.
Immatics has secured a significant collaboration with Bristol Myers Squibb to develop the TCR bispecific candidate IMA401. The agreement entails an upfront payment of $150 million, with potential milestone payments totaling up to $770 million and double-digit royalties on net sales. IMA401 targets the MAGEA4/8 antigen prevalent in solid tumors and has demonstrated promising anti-tumor activity in preclinical studies. Clinical trials are expected to start in the first half of 2022.
Bristol Myers Squibb (BMY) has secured a global exclusive license to Immatics' (IMTX) TCR bispecific program IMA401. This strategic collaboration involves an upfront payment of $150 million to Immatics, alongside potential milestone payments totaling $770 million and tiered double-digit royalties on net sales. IMA401 targets MAGEA4/8 antigens prevalent in solid tumors and has shown promising preclinical anti-tumor activity. The clinical trial is expected to start in the first half of 2022, enhancing both companies' oncology portfolios.
Immatics reported a positive update on its ACTengine® IMA203 trial targeting PRAME, showcasing a 94% disease control rate in evaluable patients and 50% achieving objective responses. The company plans to initiate three expansion cohorts for IMA203, including monotherapy and combinations with checkpoint inhibitors. Financially, cash reserves stand at $200.6 million as of September 30, 2021, though the company recorded a net loss of €27.2 million for Q3 2021, a decrease from a significant loss in Q3 2020. This news positions Immatics for potential growth in immunotherapy.
Immatics N.V. (NASDAQ: IMTX) has reported interim clinical data from its ongoing Phase 1a trial of ACTengine® IMA203, showing a 50% objective response rate (8/16 patients) across various solid cancers. Notably, 62% responded to higher dose levels. The therapy was well-tolerated, with manageable adverse events and no significant toxicities. Key findings indicate promising tumor infiltration and T cell persistence. The data will be presented at the SITC Annual Meeting on November 13, 2021, highlighting the potential of IMA203 in treating advanced solid cancers.
Immatics N.V. (NASDAQ: IMTX) has announced updates on its clinical trial ACTengine® IMA203, which will be presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 10-14, 2021. The oral presentation on November 13 will cover safety and anti-tumor activity in advanced solid cancers, while a preclinical data update on CD8 TCR-T will be presented as a poster on November 12. These updates reflect Immatics’ commitment to enhancing cancer immunotherapy.
Immatics (NASDAQ: IMTX) reported its financial results for Q2 2021, revealing a net loss of €23.8 million ($28.3 million), up from €21.3 million ($25.3 million) in Q2 2020. The company's cash and cash equivalents stood at €192.8 million ($229.1 million) as of June 30, 2021. Patient recruitment for the ACTengine® programs continues positively, with 27 patients treated by the end of July. Immatics is advancing its TCR Bispecifics pipeline, anticipating the submission of a Clinical Trial Application for IMA401 in Q4 2021. Key upcoming data releases are expected in the second half of 2021.
BioCopy AG has partnered with Immatics N.V. (NASDAQ: IMTX) to enhance T cell receptor (TCR) characterization, crucial in cancer immunotherapy. The collaboration aims to innovate high-throughput screening for TCR-peptide-HLA interactions, supporting the development of TCR-based therapies. BioCopy's patented technology can analyze over 5,000 interactions simultaneously, potentially expediting pre-clinical safety assessments. Rainer Böhm of BioCopy emphasized their unique platform addressing oncology and infectious diseases, while Immatics plans to integrate this into its XCEPTOR® platform for targeted cancer therapies.